Sequoia Financial Advisors LLC Purchases 26,656 Shares of Takeda Pharmaceutical Co. (NYSE:TAK)

Sequoia Financial Advisors LLC raised its holdings in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 70.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 64,599 shares of the company's stock after acquiring an additional 26,656 shares during the period. Sequoia Financial Advisors LLC's holdings in Takeda Pharmaceutical were worth $961,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in TAK. Blair William & Co. IL grew its stake in shares of Takeda Pharmaceutical by 8.1% in the fourth quarter. Blair William & Co. IL now owns 12,199 shares of the company's stock valued at $162,000 after buying an additional 913 shares in the last quarter. Vise Technologies Inc. grew its position in Takeda Pharmaceutical by 3.1% in the fourth quarter. Vise Technologies Inc. now owns 34,635 shares of the company's stock valued at $459,000 after acquiring an additional 1,026 shares in the last quarter. Farther Finance Advisors LLC grew its holdings in Takeda Pharmaceutical by 29.2% during the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock valued at $69,000 after purchasing an additional 1,045 shares in the last quarter. GAMMA Investing LLC grew its holdings in Takeda Pharmaceutical by 22.6% during the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company's stock valued at $105,000 after purchasing an additional 1,296 shares in the last quarter. Finally, Sage Rhino Capital LLC boosted its position in Takeda Pharmaceutical by 14.9% in the 4th quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company's stock valued at $157,000 after buying an additional 1,538 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Performance

Takeda Pharmaceutical stock traded up $0.13 during mid-day trading on Friday, reaching $15.55. The company's stock had a trading volume of 1,649,070 shares, compared to its average volume of 1,979,864. The company has a current ratio of 1.01, a quick ratio of 0.52 and a debt-to-equity ratio of 0.57. Takeda Pharmaceutical Co. has a twelve month low of $12.80 and a twelve month high of $15.53. The business has a 50 day moving average price of $14.86 and a 200-day moving average price of $14.30. The firm has a market cap of $49.48 billion, a price-to-earnings ratio of 70.69 and a beta of 0.23.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.08). The firm had revenue of $7.34 billion for the quarter, compared to the consensus estimate of $8.02 billion. Takeda Pharmaceutical had a net margin of 2.36% and a return on equity of 10.64%. Sell-side analysts predict that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.